Publications by authors named "Gabrielle Ro"
Prior hospital-based infection and risk of eosinophilic esophagitis in a Swedish nationwide case-control study.
United European Gastroenterol J
November 2022
Background And Aims: Eosinophilic esophagitis (EoE) is an increasingly common, largely food allergen-driven disease characterized by dysphagia. Prior infections are known to associate with other loss of tolerance diseases such as autoimmunity. We aimed to determine if antecedent infection was associated with later EoE development.
View Article and Find Full Text PDFObjective: Eosinophils are hallmarks in allergic type 2 inflammation and are known to release cytotoxic granule proteins that contribute to inflammation. Eosinophils develop in the bone marrow from hematopoietic stem cells and once mature, have a limited lifespan in culture, making them difficult to study . IL-33 has increasingly been shown as a key regulator of type 2 inflammation signaling through its receptor, ST2.
View Article and Find Full Text PDFIntroduction: There are limited data on the familial risk of distal eosinophilic gastrointestinal diseases (EGIDs) in patients with eosinophilic esophagitis (EoE). We analyzed the risk of eosinophilic gastritis/gastroenteritis (EG/EGE) and eosinophilic colitis (EC) as forms of distal EGIDs using International Disease Classification-9/10 codes in subjects with EoE and their relatives.
Methods: The Utah Population Database is a resource that links genealogy information and medical records in Utah.
Article Synopsis
- * Research has provided insights into EoE's pathophysiology and type 2 immunity, leading to new hypotheses and knowledge about the disease.
- * Despite advancements, there is still only one FDA-approved treatment, highlighting the need for further research and innovative methods to improve EoE management.
Article Synopsis
- Some tumors don’t respond well to treatments because they lose important signals (MHC class I) needed for immune cells to recognize them.
- A new treatment involving specific proteins (cIAP1/2 antagonists) can help the immune system fight these tumors by changing how certain immune cells (macrophages) attack.
- Using this new treatment alongside another therapy (CD47 blockade) might work even better against tough tumors that usually resist other types of treatments.